Recent Updates
Recently added Catalysts
ZTS Positive Sentiment

Zoetis Appoints Jay Saccaro as Chief Financial Officer and Chief Operating Officer

Thursday, August 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Zoetis Inc. has appointed Jay Saccaro as its new Chief Financial Officer and Chief Operating Officer, effective August 17, 2026. This newly created role will see Saccaro leading the global finance function and overseeing Global Manufacturing and Supply. His responsibilities will include shaping financial strategy and enhancing operational performance.
Price reaction · baseline $74.39 (2026-08-05 close) · hit pre-market · clean, no other ZTS news in the window
day 0 close
+3.9%
day 1
-2.3%
day 3
+1.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of Jay Saccaro as CFO and COO is a strategic move.
  • Saccaro will enhance Zoetis' financial strategy and operational performance.
  • The role indicates a focus on global finance and manufacturing efficiency.

Full Press Release Details

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced the appointment of James (Jay) Saccaro as Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026. In this newly created role, Mr. Saccaro will lead Zoetis’ global finance function, shaping capital allocation, financial strategy, reporting and controls, and investor engagement and oversee Global Manufacturing and Supply to drive operational execution and performance. With

Frequently Asked Questions

Who has been appointed as CFO and COO of Zoetis?

Jay Saccaro has been appointed as the Chief Financial Officer and Chief Operating Officer.

When will Jay Saccaro start his new role at Zoetis?

Jay Saccaro will assume his role on August 17, 2026.

What will Jay Saccaro oversee at Zoetis?

He will lead the global finance function and oversee Global Manufacturing and Supply.

What is the focus of Jay Saccaro's new role?

His role focuses on financial strategy, capital allocation, and operational performance.

ShareAdd on Google
Tags: ZTS Viatris Investor Conferences Healthcare Zoetis Jay Saccaro CFO COO financial strategy
Last updated: Aug 6, 2026

Biotech snapshot

Cash runway
$1676M liquidity · $0M/mo burn
Low dilution risk